Table 2—

CV events in the vitamin E and placebo groups

OutcomeVitamin E (n = 1838)Placebo (n = 1816)RR (95% CI)P
Primary outcome
 Composite of myocardial infarction, stroke, or CV death325 (17.7)313 (17.2)1.03 (0.88–1.21)0.70
  MI*212 (11.5)209 (11.5)1.01 (0.83–1.22)0.96
  Stroke*103 (5.6)84 (4.6)1.21 (0.91–1.62)0.20
  CV death*142 (7.7)145 (8.0)0.97 (0.77–1.23)0.82
Secondary outcomes
 Total mortality218 (11.9)232 (12.8)0.93 (0.77–1.12)0.44
 Hospitalizations for unstable angina227 (12.4)199 (11.0)1.13 (0.93–1.37)0.21
 Hospitalizations for heart failure85 (4.6)76 (4.2)1.11 (0.81–1.51)0.52
 Revascularization procedures279 (15.2)278 (15.3)0.99 (1.82–1.17)0.95
Other CV outcomes
 Any heart failure241 (13.1)201 (11.1)1.21 (1.00–1.46)0.05
 Transient ischemic attacks89 (4.8)96 (5.3)0.93 (0.70–1.25)0.64
 Unstable angina with ECG changes72 (3.9)78 (4.3)0.91 (0.66–1.25)0.91
Microvascular complications
 Overt nephropathy146 (7.9)131 (7.2)1.12 (0.88–1.42)0.37
 New microalbuminuria442 (35.3)466 (37.5)0.91 (0.79–1.03)0.14
 Dialysis9 (0.5)9 (0.5)0.99 (0.81–1.22)0.97
 Laser therapy for diabetic nephropathy182 (9.9)182 (10.0)0.99 (0.81–1.22)0.96
 New cataract/cataract surgery304 (16.5)318 (17.5)0.97 (.88–1.21)0.70
 Limb infection53 (2.9)58 (3.2)0.90 (0.63–1.31)0.59
  • Data are n (%) unless otherwise indicated.

  • *

    * A patient may have had more than one event;

  • refers to open label use of an ACE inhibitor for the diagnosis of heart failure, hospitalization for heart failure or death due to heart failure.